Navigation Links
Pharmasset Reports Positive Results from its HCV Clinical Programs
Date:1/6/2011

t, treatment-emergent trends in any clinical laboratory parameters

PSI-938 demonstrated potent antiviral activity with a median HCV RNA change from baseline of 5.23 log10 IU/mL in the 8 patients receiving 300mg QD monotherapy for 14 days. HCV RNA declined rapidly and consistently throughout the 14 day dosing period, with no viral breakthrough noted. In the 8 subjects who received PSI-938 300mg QD monotherapy for 14 days, half (4 of 8) of the subjects achieved HCV RNA below the limit of detection (15 IU/mL), and 5 of 8 patients achieved HCV RNA below the limit of quantification (43 IU/mL). The median baseline HCV RNA in patients enrolled in Part 2 was approximately 1 log10 higher than in the Part 1 multiple ascending dose trial (6.95 log10 IU/mL versus 5.92 log10 IU/mL), allowing for a full assessment of the antiviral activity of the nucleotide analog.

Patients are now being enrolled in the second and third cohorts. Patients will receive monotherapy with either PSI-938 or PSI-7977 for days 1-7, followed by the combination of PSI-938 plus PSI-7977 for days 8-14. Following availability of data from these initial combination cohorts, the fourth and final cohort will receive both PSI-938 and PSI-7977 for 14 days. We anticipate reporting further data from this study during this quarter. In addition, we plan on initiating a Phase 2 study of PSI-938 in combination with PSI-7977 during mid-2011. This Phase 2 study will explore multiple treatment durations of PSI-938 and PSI-7977 with an SVR endpoint.

"We are encouraged by the initial results generated with PSI-7977 in combination with Peg-IFN/RBV over 12 weeks and with PSI-938 monotherapy over 14 days," stated Michelle Berrey, MD, MPH, Chief Medical Officer. "Both programs are progressing on schedule and we anticipate reporting further efficacy, safety and resistance data throughout 2011. We are excited to be moving PSI-938 into the combination phase of this study with PSI-7977, as this may provide
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... , Sept. 19, 2014 Merck (NYSE: ... and Canada , is teaming with ... La Diabetes: Logra Tus Metas , an educational program encouraging Hispanics ... sugar -- a key treatment goal to help reduce the risk ... are at a higher risk for developing type 2 ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
... Scientific Resources, Inc. (OTCQB: ASFX) ("American Scientific Resources" ... Products) Ltd. ("Syner-Med") is the Company,s new distributor ... for its non-contact thermometers. Syner-Med placed an initial ... retail and professional models, of the VeraTemp non-contact ...
... LIVINGSTON, N.J., March 14 , 2011 Milestone ... develops, manufactures, and markets computer-controlled injection systems for medical ... has commenced trading on the OTCQB(TM) electronic quotation and ... not required to take any action as a result ...
Cached Medicine Technology:American Scientific Resources Announces New Distributor Syner-Med Placing Kidz-Med VeraTemp in the United Kingdom and Ireland 2American Scientific Resources Announces New Distributor Syner-Med Placing Kidz-Med VeraTemp in the United Kingdom and Ireland 3Milestone Scientific Inc. Commences Trading on the OTC Pink 2
(Date:9/19/2014)... News) -- As kids transition from elementary to middle ... to a recent study. But the researchers ... that verbal and physical bullying declines as students get ... prevention strategies must address all types of bullying as ... the researchers said. The study was published recently in ...
(Date:9/19/2014)... 2014 Hastings and Hastings, a discount accident ... industry, announces a record number of visitors to its new ... of serious injury cases as well as auto accident cases ... related accident cases and others. Having served the state of ... the test of time when it comes to dedicated and ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... News) -- Your brain structure could help predict how willing ... Researchers at Yale University found those with greater volume ... cortex may be more likely to engage in risky behavior ... The study, funded by the U.S. National Institute on Aging, ... in the Northeast. The researchers sought to determine how brain ...
(Date:9/19/2014)... (HealthDay News) -- The U.S. Food and Drug Administration approved ... is part of a class of once-a-week injectable drugs that ... diabetes. "Trulicity is a new treatment option, which ... to control blood sugar levels in the overall management of ... FDA,s Office of Drug Evaluation II, said in an agency ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... has estimated that nearly 55 percent of Americans, mostly ... of porous and brittle bones// that causes higher susceptibility ... has been found to contribute to lower bone mineral ... Katherine Tucker, PhD, director of the Epidemiology and Dietary ...
... (etanercept) safe to be used to treat psoriasis up to ... of the current studies were presented at the 15th European ... 'Biologic Medicine which means it is synthesized using recombinant DNA ... biotechnology. , , ,This biologic medicine acts by ...
... of daily physical exercise for their future good health, says ... 545 children at 36 nurseries in Glasgow. ,The ... of exercise - 30 minutes, three times a week, reported ... activity was not enough to affect the children's body mass ...
... its toll across India Thursday with over 40 people reported ... government maintained the situation did not merit an epidemic status. ... that of an epidemic and we expect that the number ... next two-three days. ,"So far we have recorded ...
... levels down for decades, ever since studies showed a strong ... years, experts have suggested that some people should aim even ... cholesterol called low-density lipoprotein for some high-risk people — even ... get there. ,Not so fast, says a team of ...
... some very interesting results following her study ... of alcoholics, which ultimately determine which drugs can be ... ,The urge to consume alcoholic drinks can be stifled ... by the researcher highlights which characteristics of a patient ...
Cached Medicine News:Health News:Consumption of Colas Increase Risk of Osteoporosis in Older Women 2Health News:Consumption of Colas Increase Risk of Osteoporosis in Older Women 3Health News:Enbrelr Enters Safer Zone After Recent Research 2Health News:India registers 3,000 dengue patients, toll crosses 40 2Health News:India registers 3,000 dengue patients, toll crosses 40 3Health News:India registers 3,000 dengue patients, toll crosses 40 4Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 2Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 3Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 4